BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes

Ishita Gupta, Allal Ouhtit, Adil Al-Ajmi, Syed Gauhar A. Rizvi, Hamad Al-Riyami, Marwa Al-Riyami, Yahya Tamimi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In Oman, breast cancer is most common, representing approximately more than 25% of all cancers in women. Relatively younger populations of patients (25–40 years) present surprisingly with an aggressive phenotype and advanced tumor stages. In this study, we investigated differential gene expressions in Luminal A, Luminal B, triple-negative and Her2+ breast cancer subtypes and compared data to benign tumor samples. We identified a potential candidate gene BRIP1, showing differential expression in the four breast cancer subtypes examined, suggesting that BRIP1 has the profile of a useful diagnostic marker, suitable for targeted therapeutic intervention. RT-qPCR and Western blotting analysis showed higher BRIP1 expression in luminal samples as compared to triple-negative subtype patient’s samples. We further screened BRIP1 for eventual mutations/SNPs/deletions by sequencing the entire coding region. Four previously identified polymorphisms were detected, one within the 5′-UTR region (c.141-64G > A) and three in the BRCA-binding domain (c.2755T > C, c.2647G > A and c.3411T > C). Kaplan–Meier analysis revealed that patients with overexpression of BRIP1 displayed a poor survival rate (P < 0.05). BRIP1 has a dual function of an oncogene and a tumor suppressor gene in addition to its role as a potential biomarker to predict survival and prognosis. Data obtained in this study suggest that BRIP1 can plausibly have an oncogenic role in sporadic cancers.

Original languageEnglish
Pages (from-to)65-77
Number of pages13
JournalEndocrine Connections
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Breast Neoplasms
Survival
Neoplasms
Oman
Triple Negative Breast Neoplasms
Sequence Deletion
5' Untranslated Regions
Tumor Suppressor Genes
Oncogenes
Single Nucleotide Polymorphism
Survival Rate
Biomarkers
Western Blotting
Phenotype
Gene Expression
Population
Genes
Therapeutics

Keywords

  • Biomarkers
  • Breast cancer
  • BRIP1
  • Oncogene
  • Overexpression

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes. / Gupta, Ishita; Ouhtit, Allal; Al-Ajmi, Adil; Rizvi, Syed Gauhar A.; Al-Riyami, Hamad; Al-Riyami, Marwa; Tamimi, Yahya.

In: Endocrine Connections, Vol. 7, No. 1, 01.01.2018, p. 65-77.

Research output: Contribution to journalArticle

@article{896c686b91c84230b5b8cbb4c56399e9,
title = "BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes",
abstract = "In Oman, breast cancer is most common, representing approximately more than 25{\%} of all cancers in women. Relatively younger populations of patients (25–40 years) present surprisingly with an aggressive phenotype and advanced tumor stages. In this study, we investigated differential gene expressions in Luminal A, Luminal B, triple-negative and Her2+ breast cancer subtypes and compared data to benign tumor samples. We identified a potential candidate gene BRIP1, showing differential expression in the four breast cancer subtypes examined, suggesting that BRIP1 has the profile of a useful diagnostic marker, suitable for targeted therapeutic intervention. RT-qPCR and Western blotting analysis showed higher BRIP1 expression in luminal samples as compared to triple-negative subtype patient’s samples. We further screened BRIP1 for eventual mutations/SNPs/deletions by sequencing the entire coding region. Four previously identified polymorphisms were detected, one within the 5′-UTR region (c.141-64G > A) and three in the BRCA-binding domain (c.2755T > C, c.2647G > A and c.3411T > C). Kaplan–Meier analysis revealed that patients with overexpression of BRIP1 displayed a poor survival rate (P < 0.05). BRIP1 has a dual function of an oncogene and a tumor suppressor gene in addition to its role as a potential biomarker to predict survival and prognosis. Data obtained in this study suggest that BRIP1 can plausibly have an oncogenic role in sporadic cancers.",
keywords = "Biomarkers, Breast cancer, BRIP1, Oncogene, Overexpression",
author = "Ishita Gupta and Allal Ouhtit and Adil Al-Ajmi and Rizvi, {Syed Gauhar A.} and Hamad Al-Riyami and Marwa Al-Riyami and Yahya Tamimi",
year = "2018",
month = "1",
day = "1",
doi = "10.1530/EC-17-0173",
language = "English",
volume = "7",
pages = "65--77",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes

AU - Gupta, Ishita

AU - Ouhtit, Allal

AU - Al-Ajmi, Adil

AU - Rizvi, Syed Gauhar A.

AU - Al-Riyami, Hamad

AU - Al-Riyami, Marwa

AU - Tamimi, Yahya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In Oman, breast cancer is most common, representing approximately more than 25% of all cancers in women. Relatively younger populations of patients (25–40 years) present surprisingly with an aggressive phenotype and advanced tumor stages. In this study, we investigated differential gene expressions in Luminal A, Luminal B, triple-negative and Her2+ breast cancer subtypes and compared data to benign tumor samples. We identified a potential candidate gene BRIP1, showing differential expression in the four breast cancer subtypes examined, suggesting that BRIP1 has the profile of a useful diagnostic marker, suitable for targeted therapeutic intervention. RT-qPCR and Western blotting analysis showed higher BRIP1 expression in luminal samples as compared to triple-negative subtype patient’s samples. We further screened BRIP1 for eventual mutations/SNPs/deletions by sequencing the entire coding region. Four previously identified polymorphisms were detected, one within the 5′-UTR region (c.141-64G > A) and three in the BRCA-binding domain (c.2755T > C, c.2647G > A and c.3411T > C). Kaplan–Meier analysis revealed that patients with overexpression of BRIP1 displayed a poor survival rate (P < 0.05). BRIP1 has a dual function of an oncogene and a tumor suppressor gene in addition to its role as a potential biomarker to predict survival and prognosis. Data obtained in this study suggest that BRIP1 can plausibly have an oncogenic role in sporadic cancers.

AB - In Oman, breast cancer is most common, representing approximately more than 25% of all cancers in women. Relatively younger populations of patients (25–40 years) present surprisingly with an aggressive phenotype and advanced tumor stages. In this study, we investigated differential gene expressions in Luminal A, Luminal B, triple-negative and Her2+ breast cancer subtypes and compared data to benign tumor samples. We identified a potential candidate gene BRIP1, showing differential expression in the four breast cancer subtypes examined, suggesting that BRIP1 has the profile of a useful diagnostic marker, suitable for targeted therapeutic intervention. RT-qPCR and Western blotting analysis showed higher BRIP1 expression in luminal samples as compared to triple-negative subtype patient’s samples. We further screened BRIP1 for eventual mutations/SNPs/deletions by sequencing the entire coding region. Four previously identified polymorphisms were detected, one within the 5′-UTR region (c.141-64G > A) and three in the BRCA-binding domain (c.2755T > C, c.2647G > A and c.3411T > C). Kaplan–Meier analysis revealed that patients with overexpression of BRIP1 displayed a poor survival rate (P < 0.05). BRIP1 has a dual function of an oncogene and a tumor suppressor gene in addition to its role as a potential biomarker to predict survival and prognosis. Data obtained in this study suggest that BRIP1 can plausibly have an oncogenic role in sporadic cancers.

KW - Biomarkers

KW - Breast cancer

KW - BRIP1

KW - Oncogene

KW - Overexpression

UR - http://www.scopus.com/inward/record.url?scp=85039699255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039699255&partnerID=8YFLogxK

U2 - 10.1530/EC-17-0173

DO - 10.1530/EC-17-0173

M3 - Article

AN - SCOPUS:85039699255

VL - 7

SP - 65

EP - 77

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 1

ER -